Despite these inconsistencies, both studies showed PI3K/AKT signaling pathways were activated by both Metf-V10 and V10 in a dose-dependent manner [83,84], suggesting that AKT hyperactivation could be one of the mechanisms of action involved, independent of the cancer cellular context. This evidence concerns the gene AKT1 and cancer.